Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie přípravku JNJ-95566692 u účastníků s nehodgkinskými lymfoidními malignitami

2. listopadu 2026 aktualizováno: Janssen Research & Development, LLC

Fáze 1, první studie nového trispecifického protilátky CD79bxCD20xCD3 na lidském organismu u B-buněčných non-Hodgkinských lymfoidních malignit (NHL)

The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

340

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

      • Clayton, Austrálie, 3168
        • Nábor
        • Monash Medical Centre
      • Melbourne, Austrálie, 3000
        • Nábor
        • Peter MacCallum Cancer Centre
      • North Ryde, Austrálie, 2109
        • Nábor
        • Macquarie University Hospital
      • Randwick, Austrálie, 2031
        • Nábor
        • Scientia Clinical Research
      • Edegem, Belgie, 2650
        • Nábor
        • UZ Antwerpen
      • Liège, Belgie, 4000
        • Nábor
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Lille, Francie, 59000
        • Nábor
        • Hopital Claude Huriez
      • Paris, Francie, 75013
        • Nábor
        • CHU Pitie Salpetriere
      • Pierre-Bénite, Francie, 69495
        • Nábor
        • CHU Lyon Sud
      • Toulouse, Francie, 31100
        • Nábor
        • Institut Universitaire du Cancer Toulouse Oncopole
      • Ankara, Turecko (Türkiye), 06200
        • Nábor
        • SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
      • Ankara, Turecko (Türkiye), 06620
        • Nábor
        • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
      • Antalya, Turecko (Türkiye), 07025
        • Nábor
        • Memorial Antalya Hastanesi Faz 1 Klinik Arastirma Merkezi
      • Istanbul, Turecko (Türkiye), 34010
        • Nábor
        • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
      • Barcelona, Španělsko, 8036
        • Nábor
        • Hosp. Clinic de Barcelona
      • Barcelona, Španělsko, 08035
        • Nábor
        • Hosp Univ Vall D Hebron
      • Madrid, Španělsko, 28041
        • Nábor
        • Hosp. Univ. 12 de Octubre
      • Madrid, Španělsko, 28040
        • Nábor
        • Hosp Univ Fund Jimenez Diaz
      • Madrid, Španělsko, 28050
        • Nábor
        • Hosp Univ Hm Sanchinarro

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 and no other approved therapies available that would be more appropriate in the investigator's judgment. -Histologic documentation of the following large B-cell lymphomas: -diffuse large B-cell lymphoma not otherwise specified (NOS), -T-cell/histiocyte-rich large B-cell lymphoma, -diffuse large B-cell lymphoma/high grade B-cell lymphoma with MYC and BCL2 rearrangements, -large B-cell lymphoma with IRF4 rearrangement, -high grade B-cell lymphoma with 11q aberrations, -Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma, -diffuse large B-cell lymphoma associated with chronic inflammation, -primary large B-cell lymphoma of immune privileged sites, -primary cutaneous diffuse large B-cell lymphoma-leg type , -primary mediastinal large B-cell lymphoma, -high-grade B-cell lymphoma NOS, -transformations of indolent B-cell lymphoma (For US sites). -Other B-cell NHL may be enrolled based on emerging data in specific cohorts as stipulated by study evaluation team (SET)
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Participants must have measurable disease as defined by the disease criteria (Lugano criteria)
  • While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate gametes (that is, eggs or sperm) or freeze for future use for the purposes of assisted reproduction; and wear an external condom; -Participants of childbearing potential must have a negative highly sensitive (for example, beta [β]-human chorionic gonadotropin) pregnancy test at screening and within 24 hours before the first dose of study treatment and agree to further pregnancy tests, -For Arm E ONLY: Practice 2 methods of reliable birth control simultaneously, including 1 highly effective form of contraception and 1 additional effective contraceptive method., -Participants on Arms C-G should also follow the pregnancy and contraception restrictions in the respective local corresponding product label

Exclusion Criteria:

  • Known active central nervous system involvement (CNS) or leptomeningeal involvement
  • Prior solid-organ transplantation
  • Malignancy diagnosis other than the disease under study within 1 year prior to the first dose of the study treatment; exceptions are squamous and basal cell carcinoma of the skin, carcinoma in situ of the cervix and any malignancy that is considered cured or has minimal risk of recurrence within 1 year of first dose of the study treatment in the opinion of both the investigator and sponsor's medical monitor
  • Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (for example, methotrexate or tacrolimus) within 3 months prior to first dose of study treatment
  • Toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia, vitiligo, peripheral neuropathy, or Grade <=2 endocrinopathies that are stable on hormone replacement)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Arm A: JNJ-95566692

Participants will receive escalating doses of JNJ-95566692 in Part 1 (Dose escalation) to determine the putative recommended Phase 2 doses (RP2D[s]) and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK (pharmacokinetic), pharmacodynamic (PD) and clinical activity.

JNJ-95566692 will be administered subcutaneously.

Experimentální: Arm B: JNJ-95566692 in combination with JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 in combination with JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 in combination with JNJ-87801493 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK, PD and clinical activity.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Experimentální: Arm C: JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493

Participants will receive escalating doses for JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Loncastuximab tesirine will be administered intervenously.

Experimentální: Arm D: JNJ-95566692 and R-GemOx with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and R-GemOx (rituximab, gemcitabine, oxaliplatin) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-GemOx with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.

Gemcitabine will be administered intravenously.

Oxaliplatin will be administered intravenously.

Experimentální: Arm E: JNJ-95566692 and lenalidomide with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and lenalidomide with or without JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and lenalidomide with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

Lenalidomide will be administered orally.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Experimentální: Arm F: JNJ-95566692 and R-CHOP with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-CHOP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

Cyclophosphamide will be administered intravenously.

Prednisone will be administered orally.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.

Doxorubicin will be administered intravenously.

Vincristine will be administered intravenously.

Experimentální: Arm G: JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

Cyclophosphamide will be administered intravenously.

Prednisone will be administered orally.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.

Doxorubicin will be administered intravenously.

Polatuzumab vedotin will be administered intravenously.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Part 1 and 2: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by Severity
Časové okno: Approximately 2 years and 8 months

An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product. Severity for AEs will be specified as per: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades which are Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (potentially life-threatening) and Grade 5 (death related to adverse event). SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

Approximately 2 years and 8 months
Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)
Časové okno: Approximately 2 years and 8 months

Number of participants with DLTs for JNJ-95566692 (arm A), in combination with JNJ-87801493 (arm B) and in arms C to G will be reported. The DLTs are drug-related toxicities and are defined as any of the following: fatal toxicity, high grade non-hematologic toxicity, or hematologic toxicity.

Approximately 2 years and 8 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Serum Concentration for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

Serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be assessed using a validated assay method.

Approximately 2 years and 8 months
Area Under the Curve During a Dosing Interval (AUCtau) in JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

AUC tau is defined as area under the serum concentration-time curve during a dosing interval (tau).

Approximately 2 years and 8 months
Maximum Serum Concentration (Cmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

Cmax for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Minimum Serum Concentration (Cmin) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

Cmin for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Area Under the Curve (AUC[0-t]) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

AUC(0-t) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Half-life (t1/2) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

Half-life (t1/2) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Time to Reach Cmax (Tmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

Tmax is the time to reach maximum observed serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Apparent Total Body Clearance (CL/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

CL/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Apparent Volume of Distribution (V/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Časové okno: Approximately 2 years and 8 months

V/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Number of Participants with Anti-JNJ-95566692 Antibodies in Arms A to G
Časové okno: Approximately 2 years and 8 months

Participants with presence of antibodies binding to JNJ-95566692 in arm A to G will be reported.

Approximately 2 years and 8 months
Number of Participants with Anti-JNJ-87801493 Antibodies in Arms B to G
Časové okno: Approximately 2 years and 8 months

Participants with presence of antibodies binding to JNJ-87801493 in arm B to G (as appropriate) will be reported.

Approximately 2 years and 8 months
Part 2: Overall Response for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Časové okno: Approximately 2 years and 8 months

Overall response is defined as a best response of partial response (PR) or better as assessed by the investigator according to standard response criteria per Lugano.

Approximately 2 years and 8 months
Part 2: Complete Response (CR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Časové okno: Approximately 2 years and 8 months

Complete response (CR) is defined as a best response of CR as assessed by the investigator according to standard response criteria per Lugano.

Approximately 2 years and 8 months
Part 2: Time to Response (TTR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Časové okno: Approximately 2 years and 8 months

TTR is defined for participants who achieved a response of PR or better as the time from the first dose of study treatment to the first response of PR or better.

Approximately 2 years and 8 months
Part 2: Duration of Response (DOR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Časové okno: Approximately 2 years and 8 months

DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease, initiation of a new systemic anti-cancer therapy or death.

Approximately 2 years and 8 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

20. ledna 2026

Primární dokončení (Odhadovaný)

31. srpna 2028

Dokončení studie (Odhadovaný)

31. října 2029

Termíny zápisu do studia

První předloženo

15. prosince 2025

První předloženo, které splnilo kritéria kontroly kvality

15. prosince 2025

První zveřejněno (Aktuální)

29. prosince 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 95566692LYM1001
  • 95566692LYM1001 (Jiný identifikátor: Janssen Research & Development, LLC)
  • 2025-523297-16-00 (Identifikátor registru: EUCT number)
  • 2025 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .